Table 2 Clinical outcomes at screening, 2 and 3 years follow up
From: Denosumab for treating periprosthetic osteolysis: a feasibility study
Denosumab | Placebo | p-value | |
|---|---|---|---|
EQ-5D | |||
Screening | 69,6 ± 17,7 | 83,6 ± 9,3 | 0.14 |
2 years | 72,0 ± 16,0 | 85,8 ± 12,3 | 0.21 |
3 years | 72,8 ± 18,3 | 80 ± 17,7 | 0.58 |
HHS | |||
Screening | 91,6 ± 9,6 | 90,4 ± 8,1 | 0.82 |
2 years | 87,6 ± 10,2 | 78,8 ± 15,2 | 0.37 |
3 years | 82,6 ± 16,6 | 88,4 ± 6,6 | 0.53 |